Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States.

Haesuk Park,Carolyn Brown,Debbie L Wilson,Pei-Lin Huang,Pilar Hernández-Con,Patrick Horne,Amie Goodin,Amanda Joseph,Rich Segal,Roniel Cabrera,Robert L Cook

SSRN Electronic Journal（2023）

引用 0|浏览7

暂无评分

摘要

These findings underscore the importance of addressing patient-related barriers and prior authorization requirements-significant problematic barriers-and improving clinicians' beliefs (e.g., medication-assisted therapy should be prescribed before DAAs) and comfort levels for treating patients with HCV and SUD to enhance treatment access for patients with both HCV and SUD.

查看译文

关键词

DAA, direct-acting antiviral,Direct-acting antivirals,GHAPP, Gastroenterology & Hepatology Advanced Practice Providers,HCV,HCV, hepatitis C virus,Medicaid,PWID, persons who inject drugs,SUD,SUD, substance use disorder,Survey,US, United States

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要